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Accessing targeted therapies for cancer: Self and collective advocacy alongside and 




As precision oncology has evolved, patients and their families have become more involved 
in efforts to access these treatments via fundraising and campaigning that takes place 
outside of the larger cancer charities. In this paper we explore the solidarities, networks and 
emotional labour of UK-based access advocates, drawing on the stories of 9 advocates, 
which included interviews and content analysis of their social media posts and coverage of 
their case in news, commentary and fundraising websites. We consider the emotional and 
knowledge work of building networks that spanned consumerist and activist agendas, forged 
individual and collective goals and orientations towards the public, private and third sectors 
as part of securing support and access. Through these various practices, the actors we have 
studied cultivated personal advantage and solidarities with other patients and advocates, 
and in so doing engaged in self and collective advocacy alongside and beyond mainstream 
cancer charities. 
 
1. Introduction  
 
Personalised medicine has become an important goal of contemporary medicine, particularly 
via tailored or targeted therapies of cancers that are designed to act on specific molecular 
targets to slow or arrest cancer growth (Ross et al, 2004).  Hailed as the ultimate form of 
individualised medicine, targeted therapies for cancer are strongly associated with personal 
narratives of hope and survival. Industry and government, together with cancer charities and 
healthcare providers across the private and public sectors, have come together to develop 
and promote access to these new opportunities through a range of trials, studies and novel 
treatments. Although filled with promise, targeted therapies are experimental, expensive and 
complex, making widespread access difficult across both insurance-based and state-funded 
healthcare systems. Pharmaceutical companies have therefore sought to increase 
awareness of their potential benefits amongst patients and doctors and accelerate regulatory 
approval of targeted therapies and companion diagnostics. For example, in 2019 Bayer 
reportedly planned to spend $70M to increase patient and physician awareness of testing for 
rare mutations and encourage regulatory approval of more tests as a means of enabling the 
use of more targeted therapies such as Vitrakvi. This targets cancers with a rare genetic 
mutation found in fewer than 1% of solid tumours. This effort includes a public awareness 
campaign, ‘Test your cancer’, that encourages patients to ask their doctors about genomic 
testing to enable early access to appropriate therapies (Steenhuysen and Burger 2019; see 
also https://global.testyourcancer.com/global). Crowdfunding for medicines has also grown 
in recent years, including for targeted therapies, promoting what Berliner and Kenworth have 
called ‘forms of individualised charity’ (2017, 233). As Lee and Lehdonvirta (2020, no 
pagination) argue these form an ‘entrepreneurial safety net: one where protection is not 
afforded universally or on the basis of need, but on the basis of one’s ability to appeal to the 
audience.’ Through these educational fundraising and media campaigns around access to 
treatments, contemporary priorities of individual empowerment, deservingness and the 
promise of cure are reinforced. 
 
Nevertheless, concerns abound in the medical and social science literatures about the hype, 
limited evidence of effectiveness and inappropriate pricing of targeted therapies for cancer 
(Davies 2015; Maughan 2017, Wiersma et al. 2019). Davies’s (2015) study of what she calls 
‘chemotherapeutic expansion’, based on interviews with cancer patient advocates, 
regulators, specialists and other stakeholders in the US and EU, suggests that experimental 
therapies with limited evidence of efficacy proliferate because of permissive regulatory 
standards, which prioritise the development of these therapies as a means to grow national 
bioeconomies, exploiting the hopes of desperate patients with advanced disease.  At the 
same time, critics have argued that ‘access-advocacy’ (Mayer 2003) does not present a 
sufficient challenge to industry practices – it is overly-reliant on and uncritical of industry 
knowledge and support, focusing instead on the failings of public health systems unable to 
finance these expensive treatments. This lack of scrutiny of industry is intensified by the 
media and charities amplifying messages of hope around cancer therapies and cure:  
 
Publication bias, distorted scientific reporting, promotional material, and stories of 
‘miracle’ drugs percolate against a background discourse of ‘science at a crossroads’ 
and ‘new eras’ (Davies 2015, 212). 
 
This renders patients vulnerable to exploitation in and through a media captured by the 
corporate interests of the pharmaceutical industry. Gabe et al.’s (2012) study of debates 
around access to Herceptin in New Zealand found that, although they are not monolithic and 
operate in ‘loose alliances’, patient and consumer groups tend not to counter, but rather 
align with industry interests, with the media playing various roles of providing information 
and constructing a ‘debate’ around access often deploying a news frame of ‘desperate’ 
patients. In a recent study of the largest US patient advocacy organisations, of which around 
30% were cancer-related, over 80% received financial support from the biotechnology, 
medical devices or pharmaceutical industry (McCoy et al. 2017). 
Hope is an important conduit through which these alliances are sustained and replicated. 
Scholarship on the political economy of hope invested in cancer therapeutics (Del Vecchio 
Good et al. 1990; Jain 2013) has demonstrated how hope enfolds the individual obligation to 
be positive and active in the fight against cancer. As Ehlers and Krupar (2014) have written, 
‘hope is now seen not as a social and collective expression of national belonging and 
welfare, but instead as something potentially embodied in one’s own biological material and 
facilitated by biotech advancements and corporations’ (2014, 396). Oncologists and patients 
become responsible for cultivating and maintaining hope, including via a ‘fighting spirit’ 
where together they will battle against barriers to access, side effects, low mood and 
mutations, enacting ‘the biopolitical imperative to enhance and optimize life’ (ibid., 407) via 
the latest ‘cutting-edge’ treatments and trials. 
Digital media platforms are increasingly important means by which patients are active and 
engaged in these individual battles (Lupton 2014; see also Viccari and Cappai 2016).  
Cancer patients are active participants in these platforms as they gather and share 
knowledge around living with cancer, taking part in research and accessing information, 
tests, treatments and care (Ziebland and Wyke 2012). Western-centric notions of 
survivorship, enablement, self-responsibility and cheerfulness are common, notably in breast 
cancer fora (Orgad 2005). As Petersen and colleagues argue, there is also growing 
emphasis on patients working with science and business on profile- and fund-raising online 
(2019). These activities are amplified and monetised by traditional media and digital media 
which ‘align with a consumer-driven model of digital patient activism’ (Petersen et al. 2019, 
489).  
 
Patient campaigns and alliances can nevertheless also involve more critical engagement 
with the interests of industry and neoliberal imperatives of positivity and empowerment. 
Barbot (2006), in a study of AIDS associations in France, suggests that their knowledge 
work can take various forms that might involve a more questioning approach, including 
orientation to science as a learner, experimental subject or citizen scientist. Here patients 
are part of new arrangements between the state and the market. Rabeharisoa et al. (2014) 
have argued that this kind of ‘evidence-based activism’ reimagines illness and its treatment 
as part of new forms of social relationships which are often condition-focused, knowledge-
laden and transformative. These activities reframe what is at stake, destabilising and 
reworking existing understandings of conditions and associated problems, working across 
and developing new kinds of expertise in the process. Although this can align with corporate 
or state-based interests, it can also challenge established institutions and practices. Breast 
cancer activists’ focus on the environmental causes of breast cancer is a good example of 
critical engagement that challenges industry to go beyond the search for cure (McCormick et 
al. 2003). O’Donovan (2007) has also demonstrated the cautious relationship of patient 
organisations engaging with the pharmaceutical industry. As Viccari and Cappai (2016) note, 
in a study of rare disease patients online, fluid connections and activities amongst patients 
can also go beyond traditional or ‘top-down’ arrangements for patient groups with defined 
leaders and institutional structures, with platforms like Facebook and Twitter being important 
means through which patients shared knowledge and developed political agendas together.  
In this article, we contribute to the study of patient advocacy, focusing on advocates’ efforts 
to access targeted therapies for cancer, which largely take place outside of established 
cancer charities and patient organisations. We explore how these activities involved 
knowledge and emotional work that aligned with and challenged individualised quests for 
self-fulfilment and cure, industry and state-based healthcare institutions. Drawing on 9 
advocate’s stories from a multi-sited ethnographic study of personalised cancer medicine, 
we explore the work and networks involved in the quest for tailored treatments and the kinds 
of capital and relationships that are formed in the process. We focus on stories of individual 
determination and deservingness as well as solidarities with other patients in accounts and 
engagements online. We argue that these cases suggest that patients and their supporters 
are not only engaging in self advocacy but also collective action which combines knowledge 
and emotional work to promotes and challenge the NHS, charitable sector and, to a lesser 
extent, the pharmaceutical industry. 
 
 
2. The Study 
 
The UK provides fertile territory for a study of individual and collective ambitions and values 
when it comes to personalised medicine given its growing private healthcare sector and 
continuing state-based provision via the National Health Services. Not all targeted cancer 
therapies are free-at-the-point-of-use in the NHS, either because the drugs have not been 
approved for use by the regulator (e.g. the National Institute for Clinical Excellence in 
England), or because the local health body (e.g. Clinical Commissioning Group (CCG) in 
England) has decided not to fund treatments for particular patients based on the details of 
their case. Typically, these drugs are only made available to a sub-group of patients with 
specific cancer types and treatment histories, via trials, private medicine or when there is 
sufficient evidence of benefit to justify their use as part of NHS care. The regulatory process 
that determines access via the NHS involves considerable dialogue and revision as 
evidence and interpretation unfold – trial data can be incomplete, local health bodies are 
subject to challenges and appeals from patients and their advocates, as are pharmaceutical 
companies accused of predatory pricing by the regulator. Charities and other advocacy and 
campaigning organisations acting on behalf of patients are also involved in these debates 
and discussions, alongside the media, who regularly profile patients seeking treatments not 
approved by their local NHS. In recent years, the phenomenon of crowdfunding has also 
grown online and patients and their supporters have begun to raise funds for targeted 
therapies in this way. The BBC recently reported that £7m was raised for cancer treatments 
via crowdfunding sites like JustGiving and GoFundMe in the three years up to 2017, 
although the proportion of funds raised for targeted as opposed to other treatments including 
alternative medicine is not known.i  
 
Our study of cancer patient, carer and advocate efforts to access targeted therapies not 
freely available on the NHS developed from a wider ethnographic study of cancer 
patienthood and genomic medicine, which was largely based around  case studies of NHS 
trials, feasibility studies and standard care involving molecular profiling, Whole Genome 
Sequencing and/or targeted therapies (see Kerr et al, 2021). We identified instances of 
access advocacy for targeted therapies for cancer in interviews with some patients, carers 
and professionals, and we conducted online searches of UK press coverage, social media, 
charity websites and patient forums. Following this process of scoping and review, we 
identified five sets of activities used by patients/carers to access drugs: self-funding via 
insurance/private treatment; crowdfunding; challenges to NHS/NICE restricted access; 
advocacy for pricing reform; and, advocacy for access to trials/more biobanking research. 
Using snowballing sampling, we went on to conduct further interviews with advocates for 
access to targeted therapies who were prominent campaigners on social media, focusing on 
the first four of these activities. We focused on these activities because they were smaller 
scale, typically patient or carer driven, and they tended to sit outside the main charitable or 
research institutions. This contrasted with advocacy for access to trials (e.g. 
actforcancer.org.uk, set up in the wake of the death of the prominent Labour politician Tessa 
Jowell, from brain cancer), which was typically more embedded in larger charitable and 
research institutions so less patient or carer led and therefore difficult to access first person 
patient and carer accounts. The bulk of our analysis is drawn from the analysis of online 
materials, supplemented by interviews with a small sample of key advocates. Accessing 
interviewees was difficult due to the ill-health of cancer patients and because the activities of 
carers and advocates were small-scale, limiting the pool of potential interviewees. The 
details of our data are set out below: 
 
 Interviews Online data sources 
(i) Self-funders 
 
Jill – bowel cancer patient 
with private insurance, 
prescribed Avastin (not 
available on NHS) [Jill’s 
relative also set up a 
crowdfunding page for 
‘alternative therapies’ for Jill] 
 
Douglas  - bowel cancer 
patient self-funding Avastin 
We interviewed Jill and 
Douglas – both were 
paying for treatments 
privately or via insurance 
schemes whilst also 
advocating for wider 
access to targeted 
therapies.  
We analysed Jill’s and 
Douglas’s blogs and Twitter 
posts. We followed their links 
to patient forum discussions, 
charitable websites and 
campaigns and analysed this 




Gillian – ovarian cancer 
patient, fundraising for 
targeted therapies that she 
may need in future and 
alternative therapies 
 
Sarah – breast cancer 
patient, fundraising for 
targeted therapies not 
available on NHS, eg 
Kadcyla 
 
Claire – breast cancer 
patient, fundraising for 
targeted therapies not 
available on the NHS eg 
We conducted 2 interviews 
with Gillian and Sarah. 
We analysed Gillian’s and 
Sarah’s and three other 
crowdfunding fundraising 
pages (Claire, Tom, Rachel) 
and their blogs/ 
Twitter/Facebook/Instagram 
posts. We also analysed 
media coverage of these 
patients’ stories [with 
permission to quote from 
Gillian and Sarah] 
Kadcyla 
 
Tom – bowel cancer patient, 
fundraising for targeted 
therapies not available on 
NHS eg Avastin 
 
Rachel – ovarian cancer 
patient, fundraising for 
targeted treatment not 











We interviewed Sasha, a 
carer who became a 
campaigner and set up a 
foundation for cancer 
patients seeking the 
challenge NHS decisions to 
refuse access to targeted 




We analysed the foundation 
website and Sasha’s social 








We interviewed Mark, an 
activist advocate who set 
up small campaigning 
foundation to advocate for 
patients seeking access to 
targeted therapies (for 
cancer and other diseases) 
focusing mainly on 
challenging pharmaceutical 
companies pricing policy 
and NICE decision-making 
 
We analysed the advocacy 
foundation website, including 
features on patient 
ambassadors, associated 
social media posts, 
academic reports linked to 
the campaign, media 
coverage, and political party 
policy making [with 










4 blogs (Jill, Douglas, Gillian, 
Sarah) 
5 fundraising pages (Gillian, 
Sarah, Claire, Tom, Rachel) 
2 foundation websites 
(Sasha, Mark) 
5 Twitter accounts (Jill, 
Douglas, Gillian, Sasha, 
Mark) 
2 Facebook accounts 
(Gillian, Claire) 
1 Instagram accounts 
(Gillian) 
Patient forum discussions 
(Jill, Douglas) 
Newspaper and TV 
coverage (Douglas, Gillian, 
Sarah, Claire, Tom, Rachel, 
Mark) 
Charity website (Jill, 
Douglas, Gillian, Sarah, 
Claire, Rachel) 
Various academic reports 
and political party policy 
documents (connected to 
Mark’s foundation) 
  
In the analysis that follows we explore the knowledge and emotional work of forging 
networks and support, including orientating to institutions (NHS, charities) and industry 
(pharma), and framings of individual and collective problems and solutions, particularly in 
relation to entrepreneurialism, hope, consumption and solidarity. We have given our 
participants pseudonyms and all data was collected with appropriate University ethical 
approval.ii We utilised situational analysis as a theory/methods package to capture and 
analyse the situations, commitments and controversies in which advocates operated, 
attending to complexities of discourses, agencies and structures (Clarke 2016). 
 
3. Analysis 
3.1 Building networks 
 
Being a cancer patient is a full time job,” says Spurrier. “If you want some normality, 
like non-patients have, then you have to be extremely organised and 
knowledgeable… Patients invest everything in their treatment and survival, much of 
which is unrecorded and unevaluated, but we are not nearly as good at managing 
and optimising the impact of it on our lives as engaged, chronic patients sometimes 
are. (Wagstaff 2017) 
  
It is widely acknowledged that a cancer diagnosis brings with it a lot of work to try to stay 
well or get better by gathering knowledge, managing schedules, relationships and emotions 
(Gibson et al. 2015; Jain 2013; Hubbard et al. 2010; Martin and Finn 2011). For some 
patients, accessing targeted therapies not otherwise available as part of public-funded 
healthcare can become a vital part of this work – researching options, sharing experiences 
with others in similar situations, advocating for policy, institutional or industry changes, and 
fund-raising for treatments.  
 
In our study we found that tending to wide-ranging networks of people engaged with or 
affected by  similar types of cancer  (depending on its origins in the body, stage and genetic 
sub-type) or seeking the same or other similar targeted therapies was fundamental to 
gathering support, influence and opportunities for this kind of campaigning and advocacy. 
On-line networking was particularly important, not just for those actively seeking donations 
on crowdfunding platforms towards their own treatment, but for others seeking to raise their 
profile in order to recruit allies, clients or cases to campaign around. For access advocates, 
this included developing an array of online activities such as blogs, social media accounts on 
Twitter, Instagram and Facebook pages, petitions and photoshoots as well as coverage by 
their local newspapers, national press, charity websites and short films and in some cases 
television coverage on news channels and documentaries.  As Van Dijck and Poells (2013) 
have noted, these processes of cross-syndication entwine social and mass media logics. 
Attending to and extending workplace, patient, family and friendship networks was part of 
sourcing support and donations. This could include connections to journalists to gain 
coverage about their situation, often via local papers taking up their stories. For example, 
one crowdfunding patient, Tom, had a relative who was a journalist and he also got 
coverage of his situation in the national press because of his existing profile as a worker in 
the cultural industries. Coverage of awards such as Campaigner of the Year or Inspirational 
Woman of the Year from charities, in local media outlets was a feature of this work too.  
 
This networking spanned professional and patient contacts.  After one of her parents died 
from cancer, Sasha told us how she curated a range of contacts in oncology as part of the 
campaigning work she developed, and sought out clients to leverage influence:  
 
It’s really important for me to keep that contact, because that, for one, keeps me 
knowledgeable about what the actual process is … what they’re going through, and 
another gives me a really powerful patient group … that are behind me, that … 
obviously need the change.  
A notable feature of these networks was how they spanned different kinds of advocacy and 
fund-raising practices, sharing knowledge, experiences and support and campaigning with 
self-funders and crowd-funders, people who were fortunate to have access to insurance and 
others who were not, and encompassing consumerist and activist agendas. Sasha and 
Mark, for example, were working on different tactics to improve access to a range of 
targeted therapies, with Sasha developing networks with wealthy philanthropists and private 
physicians as well as patients and their families to advocate for patient consumers and 
challenge the NHS, whereas Mark was networking with other activists and campaigners in 
the UK labour movement, as well as patients and their families to challenge pharma, some 
of whom also worked with Sasha.   
 
Ensuring the diversity and flexibility of networks was connected to the need to build support,  
followers and ‘likes’ online. For advocates with a professional background in an adjunct field, 
which included public relations professionals, writers, public speakers or teachers, this could 
involve providing press packs, which included a note of follower numbers on the main social 
media platforms. But extending networks was important for others too. For crowdfunders this 
was a matter of generating more donations. For more entrepreneurial advocates who had 
developed a livelihood connected to their cancer advocacy – sourcing funds and clients for 
their foundation, selling their books or art, teaching or coaching – it could also generate 
more income. However, even for the advocates who were not directly involved in raising 
funds, networks were important as a means of developing social and emotional support, 
recognition and self-worth. As Gillian wrote in her blog: 
 
… it’s friends old and new rallying around me, sending me gifts, and keeping me 
amused and entertained throughout that I have been, and continue to be, most 
overwhelmed by. Cancer is all-consuming, relentless and exhausting, but worst of all 
it’s lonely. That is why I am eternally grateful to you all for sticking with me and 
keeping me afloat. It goes some way to counteract the truly darkest of days. 
 
Experiencing and performing validation was important in and of itself for those seeking funds 
for treatment too, so much so that their identity as a cancer patient and an accomplished 
writer, sports person or campaigner, came to the fore in some of their networking rather than 
their efforts to raise funds or advocate for tailored treatments. In some media or blog 
discussions on their situation their crowdfunding activities, the details of their cancer or 
tailored drugs sought were not mentioned at all. Rather the focus was on their 
accomplishments or campaigning work, sometimes, though not always, in alliance with 
charities – for example, in one media article about Tom, his flourishing creativity was the 
focus; and in Gillian’s blog her many awards, invitations and features in the press were 
celebrated as ‘honours’ or ‘highlights’.  
 
These overlapping, flexible and multiple networks (Viccari and Cappai 2016) spanned a 
range of political and economic positions and agendas, and in so doing combined individual 
and collective kinds of advocacy involving considerable emotional as well as knowledge 
work, as we now go on to consider in more depth. 
 
 
3.2 Individual and collective advocacy 
 
As we have already discussed, advocates’ efforts to access targeted therapies were part of 
a wide repertoire of entrepreneurial activities, such as working as educators, artists, writers 
or campaigner with cancer and treatment access motivating and becoming a focal point for 
their outputs. For example, following on from her experiences of trying to access a particular 
targeted therapy for a parent with cancer, Sasha developed a full-time campaigning role, 
advocating for patients refused access to other kinds of targeted therapies by NHS 
commissioners. Developing a network of patients unable to access treatments was also 
important for other self-funders and advocates in our study like Mark and Jill, who gave 
coverage and support to these cases to extend their network and amplify their campaign. 
This involved a range of knowledge and emotional work. Sasha stressed the way in which 
her campaigning work built upon and developed her public relations skills and knowledge of 
NHS Commissioning, inventing a new kind of role that the NHS should embed in their 
services –drawing on her passion and drive to improve access to present herself as a 
trouble-shooter who could improve a failing service.  
 
Crowdfunders were entrepreneurial in sourcing ‘individualised charity’ (Berliner and 
Kenworth 2017, 233), including through developing support networks, profiling and 
organisation of a range of fundraising activities for their cause. This was often done indirectly 
– fundraising sites were sometimes hosted by relatives or included posts that raised the 
profile of relatives and friends raising funds on their behalf, for example through different 
kinds of charity concerts and sporting pursuits, amplifying the positive emotions of  making a 
difference by fundraising and expressing gratitude without directly asking for donations to 
their own healthcare. 
 
However, these activities also went beyond individual advocacy, cultivating solidarities with a 
purpose beyond individual goals of accessing targeted therapies, encompassing advocacy, 
advice and care for other patients, with some crowdfunders featuring as ambassadors in 
Mark’s foundation’s campaigns, for example. Private funders were similarly engaged in acts 
of solidarity with other patients and carers, as access to targeted therapies became a 
collective rather than a straightforwardly individual problem. Their focus was on the 
entitlements of cancer patients to access the right drugs for their cancer rather than on 
particular drugs or even cancer patients with particular molecular subtypes of cancer. 
Advocates also used their social media platforms to profile and lend support to other 
advocates and campaigns, including the work of charities on wider awareness-raising 
campaigns focusing on screening and prevention, for example. 
 
The entrepreneurial spirit was entwined with a collective ethos in these various individual 
and collective pursuits, spanning efforts to achieve transformation for self and others, 
marked by emotions of hope but also concern for others, courage and determination. For 
example, in a discussion about what motivated her to become a writer, teacher and 
advocate for herself and other patients, Gillian wrote in her blog:  
 




Being part of a community seeking change involved encouraging donations and profiling of 
others seeking targeted therapies and giving advice about new trials or treatments abroad 
that might be useful and making an emotional connection with others.  For example, in one 
comment on one of the fundraising sites, we analysed an anonymous donor wrote:  
 
I know my donation is small but I hope it helps a little – I have also started a go fund 
me for my husband as he is struggling through cancer right now. One thing we found 
very helpful was looking at personal diagnostics. You should check our Craig 
Venter’s Health Nucleus. That’s what we’re trying to raise money for. Hang tight and 
stay strong. 
 
Arguably this advice magnified individual goals of personalisation, but it also offers 
reciprocal care and support in a collective sense.  
 
Obligations to keep fighting cancer were also tied to frequent expressions of gratitude or 
demonstrations of deservingness, often linked to a sense of obligation to stay positive, well 
or alive for children or spouses. This included accounts of a sense of reciprocity to donors 
and other supporters, as well as ‘giving back’ to the NHS or cancer community more 
generally. We found both an individual and collective ethos in accounts and videos that 
access advocates posted about their experience or reactions to donations or support from 
others. In one video Tom’s tearful partner tells us about her gratitude to donors and tells 
poignant stories about people who have donated after their own cancer experiences, 
reflecting that this is because people are responding to Tom’s goodness and his 
contributions to other people’s lives through his creative work. Here individual attributes and 
deservingness and collective values of compassion and empathy for others were mutually 
reinforced. 
 
These stories of connection emphasised comfort as well as shared resolve. For example, 
Claire, another crowdfunder, made requests for donations on her blog and expressed hopes 
that her own health would improve as a result of targeted therapies becoming available to 
her, but she also wrote about how important it was to share her story with and meet other 
women affected by cancer, for example on a course she recently attended, as it offered 
hope for the future. Access advocates built a profile and a platform online which went 
beyond sharing knowledge, sourcing funds or advocating for individuals to be able to get 
targeted therapies on the NHS, to encompass the emotional work of caring about the lives of 
cancer patients more generally, be that patients with the same cancer (e.g. being positive 
about ‘living life’ with other ‘stage 4 bowelies’), or challenging the UK government to 
reassure ‘cancer friends’ about the supply of cancer drugs post-Brexit.  
 
 
As we’ve discussed, hope was important throughout these cases, but it sat alongside other 
emotional work around individual and collective deservingness, modesty and vulnerability. 
For example, in one post Claire appealed to her deservingness by giving an account of her 
hopes and doubts. She wrote about how her clinicians were happy that she has new tailored 
treatment options on the NHS, but she was doubtful because she had become used to 
having her hopes dashed and could not believe this will be any different. Claire vowed to 
continue researching her cancer and raising funds but acknowledged it’s not so urgent now 
she has other treatment options. She ended her post with a joke about a haircare gift being 
a sign of her optimism.  Elsewhere on her blog Claire focused more on collective agendas 
for access and care, joining together with other kinds of access campaigns, including those 
run by charities. She noted the sense of purpose that these activities gave her and 
emphasises the reciprocities involved – asking for help with campaigning to support her 
because of her own track record in supporting others. 
 
Douglas also expressed modest hopes for his own future in his posts about his experiences 
of cancer where he includes discussion about self-funding: 
I’ve been self funding to the tune of a little over £10,000 for 6 treatments! Despite 
being available in other countries, in the UK [the drug’s] effectiveness … is viewed as 
inconclusive. In my position (and luckily I can afford it for now) I felt compelled to give 
it a go. 
… I received the result of my latest scan and it was a mixed bag! The tumours … 
responded well to treatment and have reduced nicely. But unfortunately I’ve got 
some tough little bastards in my lungs and they’ve actually grown. The long and the 
short of it is that I’ll be back on chemo … in 3 weeks time. … It does seem that 
perhaps the tide of good news is beginning to turn. While I’m realistic, don’t bet on 
me not beating the odds! 
Here Douglas, like Claire, calibrated his hopes and tried to be realistic, given his prognosis. 
Disappointments were moderated by humour and maintaining hope about ‘beating the odds’. 
We can also find other kinds of appeals to collective benefits and hopes on Douglas’s social 
media alongside these more individual stories. For example, Douglas reflected in one blog 
post about what is good about living with cancer, including getting together with friends to 
fundraise for a charity. He continued: 
We all have different ways of coping, but the disease can be quite isolating, and I 
really believe that there are amazing benefits to be had through sharing with others 
going through similar experiences. Many have extraordinary stories and all have 
been through tough times, but there is a real sense of “we’re all in this together.” 
Access advocacy could also generate as well as counter difficult emotions. In the case of 
crowdfunders in particular, cultivating interest and support by posting intimate details of their 
daily life and illness experiences or displays of emotion online could be wearing, as could 
frequent attendance at fundraising events organised by supporters. For some this generated 
anxiety about meeting the expectations of donors or other patients who were also 
fundraising e.g. donating to others or offering advice about how to fundraise. Here the 
obligations of supporting and building networks came to the fore. Engagement and advocacy 
for access more generally could also generate distress. For example, in a media feature 
about one of the crowdfunders in our study, the writer noted Tom’s passion and 
determination to see improvements in cancer care promised by personalisation and his 
difficulties with managing the anger and distress he felt about the impact of the current 
political situation on cancer services and health care more generally.  
 
3.3 NHS, Charities and Pharma 
 
As the discussion thus far has illustrated, self and collective advocacy involves a plethora of 
knowledge and emotional work, including in relation to the NHS, charities and the 
pharmaceutical industry, and it is to this that we now turn to consider in more depth.  
 
We found that access advocates were especially engaged with the role of the NHS in 
providing targeted therapies. Even for patients accessing treatment privately, the NHS was 
where their treatment had begun, and accessing therapies privately often took place on NHS 
premises or in combination with other kinds of care freely provided by the NHS. 
Considerable emphasis was placed on the need for the NHS to deliver these treatments at 
no cost, across advocates’ activities and accounts, whatever their approach to funding 
treatment. Sometimes this involved challenging commissioning bodies, as in Sasha’s case, 
where the NHS was cast as a faceless and outdated bureaucracy, as in the tweet below: 
 
Last night I received desperate letters of a man fighting bureaucracy to stay alive. 25 
yrs old, no "standard" cancer treatment left... His peers in the US are receiving 
immunotherapy – he can't understand why he can't have the same and a chance to 
live. I'll fight for him now... 
 
 
Emotive comparisons with the treatments available to patients in the USA were used by 
Sasha to advance the case for better access in the UK. At other times advocates focused on 
drawing patients together with political activists to campaign against US-based 
pharmaceutical companies and pressuring NICE to enable the NHS to deliver the best 
available treatments, as in Mark’s case. Other patients worked on campaigns with political 
parties and charitable bodies that included but went beyond efforts to access particular 
targeted treatments.  For example, one crowd-funder, Claire, worked with a breast cancer 
charity to campaign for everyone to get the treatments they needed and also featured in 
their campaign about how the NHS is failing women with breast cancer because of delays in 
diagnosis.  
 
Yet advocates also praised and expressed support and devotion to the NHS across their 
digital content and interview accounts. Mark worked with political parties to advocate for new 
modes of pharmaceutical pricing to protect the NHS from profiteering. Claire met with 
politicians and worked with another access-advocacy group where her story was featured on 
their website and she positioned herself as a supporter of the NHS, criticising government 
under-funding. Others commented on media reporting about waiting lists and political party 
policies on the NHS. Tom, for example, criticised the government for trying to privatise the 
NHS and the effect this would have on those living in poverty and called for support for the 
NHS. The NHS was also positioned as struggling to provide by other crowdfunders, such as 
Rachel, who sought to pressurise the NHS to provide treatments at the same time as she 
expressed gratitude to its staff for the care she has received.  
 
In an interview with another crowdfunder, Sarah, we can see how orientation NHS could be 
a matter of careful reflection about tensions around privilege and solidarity: 
 
I'm fortunate enough to be in a position where I am able to write up my story in an 
articulate … logical manner… as clearly as I can so that people know exactly what 
I'm fundraising for and why I'm doing it.  … not everyone is a position to be able to do 
that …. that is really sad because … we're discriminating against people who need 
… the help as much as anyone else.  … So we're coming back to… poor people 
being worse off … it's all becoming like a two-tier system, … and it … should be … 
healthcare for all.  That's the premise of the NHS and … it's dividing people again. 
As this quote illustrates, even for self-funders, solidarity with patients and the collective spirit 
of the NHS was important. 
 
Personal links to charities were also important for the advocates we studied. These also 
spanned self and collective advocacy. These links were built through advocates re-posting 
social media material from charities, acting as ambassadors for campaigns, appearing in the 
media or in short films for the charity as well as attending charity events and meetings. 
 
As we’ve already discussed, patients like Claire worked with particular charities to advocate 
for prevention and access to treatments, including features about their case in short films 
and articles on charity blogs, sometimes also featuring in news media. Whilst these activities 
did not raise funds for drugs directly they did create reach and likeability - vital to extending 
networks of potential donors. However, engaging with charities, like engaging with other 
patients and carers, was not simply instrumental; instead it was part of cultivating a sense of 
solidarity and compassion. This was part of being an advocate beyond access to medicines 
for oneself, as Gillian noted: 
 
…so I support  … the two ovarian cancer charities and raise money for them just to 
try and get the awareness around that. But … I don't know … [it doesn’t get more 
attention] it's not… sexy enough [as compared to breast cancer where there is more 
campaigning and funding] 
 
Gillian’s campaigning included appearing in teal coloured underwear as part of ovarian 
cancer awareness week, one part of a busy cancer-based working life, writing, teaching and 
healing others. Note, however, that elsewhere Gillian reflected on her blog about the need to 
centre on herself and reduce the amount of campaigning and support she offered to others 
as her illness advanced.  
 
Crowdfunding advocates also signposted donors and supporters to particular charities on 
their fundraising sites. This included indicating how their funds would be used to support 
charities if they were not used for treatment costs, and updates about charity events 
attended. Crowdfunders also got involved in fundraising for charities when their illness had 
abated, for example Rachel posted a link to a sponsored sporting event she was 
participating in as part of fundraising for a local hospice on her crowdfunding page. 
 
Just as with tensions around criticising and supporting the NHS, at time advocates also 
become involved in criticising charities, as one self-funder, Jill, explained. Jill experienced 
charity sites as problematic from the start of her cancer: 
 
I was getting very, very frustrated that … the general ethos was ‘be positive and don't 
worry about life, eat lots of cake and be happy 
 
Here Jill found the ethos of positivity and hope cultivated by charities jarred with her own 
drive to improve care. She intervened, asking other patients what tests they’ve had and 
discussing diet, but was asked by moderators to avoid giving dietary advice, as this should 
be the province of bona fide experts. Although this decreased her engagement with charities 




With the [drug] issue … – and that was when I wrote my blog post – … it was such a 
contentious issue for me that I contacted [a charity] because I thought… if I go to 
NICE and challenge them, they're just gonna bat me away, I’m one person.  But if I 
can do it through … the cancer charity, perhaps they've got … a bit more voice.  And 
I said to them, "Look, I would be prepared to head up the campaign, do all the work 
for it, alongside other patients because there are a few patients who are quite willing 
to do it, but we need your name and your guidance.… to know exactly who we 
approach."  And they just said to me they're not interested … in pursuing it because 
they've tried before; NICE have said no, it's very unlikely they're ever gonna change 
their mind on it, so there's no point in challenging it anymore.  
 
This experience led Jill to set up her own closed Facebook group to support and advocate 
for other patients who seeking tailored treatments, including through crowdfunding, although 
she maintained a link with the charity and their CEO later joined in the Facebook group.  
 
There was less engagement with and critical reflection about the pharmaceutical industry 
across the accounts we analysed, although there were also clear instances of criticism from 
some actors, notably Mark, Tom and Claire. The focus of this criticism was on profiteering, 
as Mark noted, saying that his campaign work is: 
 
very much focused on the responsibility of first and foremost, the pharmaceutical 
companies, for … charging a price which is justifiable and affordable, and ethical. 
 
However, for campaigners like Claire, alliances were also built with pharma, for example 
when she spoke at and event sponsored by industry to share her story and build awareness 
of the needs of patients like her. Sasha also told us she had ‘made a conscious decision not 
to get involved with the pharmaceutical pricing’ in her campaign work and to remain focused 
on the NHS.  Although she articulated support for other campaigns that were critical of 
excessive pharmaceutical pricing, she also went on to praise the good work of the industry, 
expressing concern that they could be ‘unfairly demonised’, and noting that she has ‘met 
some really lovely people within the industry that are doing amazing things’ to facilitate 
patient access.  Other patients were also ambivalent or largely silent about criticism of 
pharmaceutical companies. For example, Gillian, a blogger with an extensive repertoire of 
connections to charities and cancer writing and support work, positions pharmaceuticals as 
‘Western medicine’, which she uses alongside traditional therapies, seeing this as one part 
of her activities as a warrior against cancer, and did not engage with questions of the ethics 
of pricing or pressures on the NHS.  
 
 
4. Discussion and conclusion  
 
The range and variety of these accounts of the NHS, charities and pharmaceutical industry, 
above, demonstrate that these kinds of access advocates combine self and collective 
advocacy in complex and diverse ways. They are cannot be sorted into categories of 
passive dupes, naive consumers or antagonists. Although there was not a great deal of 
critical engagement with pharmaceutical industry practices the efficacy of the kinds of 
tailored treatments being advocated, and a tendency to focus on the problems of the NHS 
(Meyer, 2003), this was complicated by other kinds of critical engagement with industry and 
NHS funding which shifted the discussion to wider political and economic processes. 
Consumer-oriented logics of entitlement to access tailored therapies to extend individual 
survival and benefit sat within a wider terrain of hopefulness for equity for other and future 
patients and services, where solidarity came to the fore. Here we see a version of 
Rabeharisoa et al.’s (2014) ‘evidence-based activism’ not only reimagining illness and its 
treatment as part of condition-focused patient collectives, but tentatively reimagining the 
relationship between patients, charities, the health service and industry. 
 
As targeted therapies for cancer evolve, so too do the ways in which patients and their 
supporters advocate for access for themselves and others. Traversing analogue and digital 
worlds, creating new networks and livelihoods, working through their orientations towards 
the state, the third sector and the market, participants in our research were engaged in self 
and collective advocacy around patient access to targeted therapies and improvements in 
care more generally. Connected by shared but nonetheless at times contradictory and 
inconsistent hopes and aspirations, these advocates were neither simply individual 
consumers  of particular treatments or collectivised critics of pharma or the NHS, but instead 
were involved in building common causes and shared agendas with an array of patients, 
supporters and advocates alongside efforts to access particular treatments for their cancers. 
Hopeful attention to the possibilities of their own therapeutic salvation interspersed their 
accounts and activities, but it would be wrong to cast this as naïve or misguided, as their 
hopes were shot through with critical self-reflection and concern for others. Developing their 
networks as a way to enhance and extend their life also involved sometimes uncomfortable 
and difficult interactions and exchanges with social and other media providers as details of 
intimate experiences are made public in exchange for the possibility of more support. These 
networks brought together people with similar cancers or seeking similar drugs but also 
included connections to patients and supporters with different illness experiences, 
backgrounds and political orientations in common cause, as they worked to support and 
encourage each other in their quest for tailored therapies. Personal goals for tailored 
treatments that would extend life were articulated through and in relation to a more collective 
set of aspirations and goals, where solidarity and equity were key shared concerns. 
 
Social scientists have framed drug development and uptake as a process of 
‘pharmaceuticalisation’ – ‘[t]he transformation of human conditions, capacities or capabilities 
into opportunities for pharmaceutical intervention’ (Williams et al. 2011, 711), highlighting the 
lack of critical engagement of patient advocate and their supporters. But our study suggests 
that there is more diversity, scepticism and critical self-reflection in the work of access 
advocates than this framing implies. Hope was a key aspect of their activities, but this was 
not uncritical and could involve critique of charities, industry and the NHS. Hope also formed 
one part of a much wider plethora of emotional work that took place alongside the 
knowledge work of network building, individual and collective activism and engagement with 
institutions and industry.  
 
Our analysis suggests the need to further examine the confluence of knowledge and 
emotional work that make up patient and their supporters’ individual and collective quest for 
access to targeted therapies as personalised medicine advances. We need to consider 
further the intersections of digital and analogue worlds and profiles, and the wider terrain of 
collective and individual advocacy this involves. We have begun to sketch out some of the 
orientations to the NHS, charities and pharma of advocates, but further work is needed to 
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